Predict your next investment

FOOD & BEVERAGES | Ingredients, flavoring & condiments
kaleidomyco.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About KaleidoMyco

KaleidoMyco focuses on combining hemp extract, adaptogens and myco based ingredients to produce data-driven, science-based wellness products.On April 7th, 2021, KaleidoMyco was acquired by Global Wellness. The terms of the transaction were not disclosed.

KaleidoMyco Headquarter Location

Florida,

United States

Latest KaleidoMyco News

Health and Wellness Stock News: Global Wellness Strategies (CSE: LOAN) and KaleidoMyco Introduce One-Shot Drink Combining Functional Mushrooms with Hemp Extract

Apr 26, 2021

Health and Wellness Stock News: Global Wellness Strategies (CSE: LOAN) and KaleidoMyco Introduce One-Shot Drink Combining Functional Mushrooms with Hemp Extract The one-shot utilizes proprietary extraction technologies for a refreshing on-the-go beverage   Vancouver, British Columbia - April 26, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRD) ("GWS" or the "Company") (formerly Redfund Capital Corp.) and KaleidoMyco, one of the first companies combining hemp extract and adaptogens, introduces its flavored antioxidant one-shot beverage combining functional mushrooms with hemp extract. KaleidoMyco is combining 50 milligrams of hemp extract with functional mushrooms to launch a new one-shot wellness beverage utilizing its proprietary extraction techniques. KaleidoMyco will launch a blend of functional mushrooms in three likeable flavors including lemon lime, orange citrus, and grape. The concept of a wellness shot designed for health benefits is not novel but in recent years they have gained traction at vitamin shops, fresh-pressed juice bars, and grocery stores. The 60-100oz tiny drinks often promise immune boosts and weight loss. Consumers flock to them and many of the most popular wellness shots on the market are now plant-based extraction products like KaleidoMyco's new hemp-myco shot. In recent years functional edible mushrooms have attracted attention as a commercial source of antioxidants. Various anti-inflammatory compounds and substances in functional mushrooms offer relief from arthritis, muscle strain, and other common inflammatory conditions. It has been said that these mushrooms help stabilize the immune system and that they boost the body's defenses and even the production output of white blood cells1. "The team at KaleidoMyco are innovators, mycologists and formulists, who look to introduce new wellness products that help consumers take care of themselves first. It is a boost to our minds and bodies not a cure is their philosophy and a theory that resonates during COVID 19. Bringing revenues to the bottom line in short order continues to be their fiscal mandate. We anticipate an online storefront and digital rollout on platforms such as Amazon shortly. A direct sales network plus distributors should be in full-swing by end of the next quarter," stated Meris Kott, CEO of Global Wellness Strategies Inc. About KaleidoMyco KaleidoMyco is one of the world's first companies combining hemp extract, adaptogens, and myco-based ingredients to produce world-class, data-driven, science-based wellness products. It is dedicated to driving ground-breaking innovations in the production and delivery of myco-derived formulations. KaleidoMyco has a team of experts who are actively working to lay the foundation in the psilocybin space as more developments in regulation become available. About Global Wellness Strategies Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, hemp and CBD, healthcare-related target companies. For further information, please visit our website: info@globalwellnessstrategies.com Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. 1 Kozarski M.S., Klaus A.S., Niksic M.P., van Griensven L.J.L.D., Vrvic M.M., Jakovljevic D.M. Polysaccharides of higher fungi: Biological role, structure and antioxidative activity. Chem. Ind. 2014;68:305-320. doi: 10.2298/HEMIND121114056K More Info: This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing KaleidoMyco

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

KaleidoMyco is included in 1 Expert Collection, including Cannabis.

C

Cannabis

3,834 items

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.